Document Detail

Effect of recombinant human erythropoietin administration on immunological indices in patients undergoing chronic hemodialysis.
MedLine Citation:
PMID:  8255010     Owner:  NLM     Status:  MEDLINE    
In patients undergoing chronic hemodialysis, marked anemia may cause decreased immunological function. To improve this anemia, we investigated the effect on immunological indices of recombinant human erythropoietin (rHuEPO) administration in 24 hemodialysis patients (13 males and 11 females) with renal anemia complications. Their mean age was 54.9 +/- 14.8 years and the mean duration of dialysis was 100.5 +/- 54.9 months. The subjects were treated with rHuEPO for 12 months, which helped to maintain a hematocrit value elevated by 5% from the baseline. Cell-mediated immunity and humoral immunity were assessed prior to as well as throughout the treatment period. Of the total number of patients studied, the anemia of 16 improved while 8 did not show signs of sufficient improvement. The improved group showed an increase in in vitro lymphocytic response to phytohemagglutinin (PHA), CD4/CD8, CD16 and serum IgM levels, while the CD8 level decreased significantly. Improvement in the general physical condition with rHuEPO treatment appeared to be associated with the changes in immunological indices, but the precise mechanism remains obscure.
N Yorioka; N Hamaguchi; N Takasugi; K Shigemoto; S Harada; K Fujiwara; A Ishida; T Maeda; A Kawai; M Yamakido
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nihon Jinzo Gakkai shi     Volume:  35     ISSN:  0385-2385     ISO Abbreviation:  Nihon Jinzo Gakkai Shi     Publication Date:  1993 Aug 
Date Detail:
Created Date:  1994-01-10     Completed Date:  1994-01-10     Revised Date:  2011-08-01    
Medline Journal Info:
Nlm Unique ID:  7505731     Medline TA:  Nihon Jinzo Gakkai Shi     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  981-8     Citation Subset:  IM; X    
Second Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / immunology,  therapy*
CD4-CD8 Ratio
Erythropoietin / administration & dosage*
Lymphocyte Subsets*
Middle Aged
Recombinant Proteins / administration & dosage
Renal Dialysis / adverse effects*
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of high-dose vitamin B6 therapy on microcytic and hypochromic anemia in hemodialysis patient...
Next Document:  Effects of recombinant human erythropoietin (EPOCH) on the coagulation and fibrinolytic systems and ...